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Age related macular degeneration (AMD) is one of the 
leading cause of visual impairment in developed 
countries [1,2]. AMD has been classified in two major 
clinical patterns: the “dry” form which is associated 
with an atrophic evolution and a slow visual decline and 
the “neovascular” form which is characterized by 
choroidal neovascularization (cnv) associated with a 
rapid and abrupt visual loss [3,4].  
 
AMD is the result of a complex interaction between 
environmental factors and genetic.  Smoking is the most  
 
consistently identified modifiable risk factor, but dietary 
factors, solar insolation, and season of birth may also 
affect AMD incidence and progression [5,6]. The patho-
genesis of neovascular AMD has long been debated but 
at present it remains not fully elucidated. It encom-
passes the presence of an inflammatory network 
involving the macula and the active role of pro-angio-
genic factors which lead to choroidal neovascularization 
and visual loss [7]. 
 
Among the various pro-angiogenic factors, vascular 
endothelial growth factor (VEGF) seems to play a 
pivotal role in neovascular AMD, and actually anti-




























ophthalmic  examination  including  best  corrected  visual  acuity  (BCVA),  applanation  tonometry,  slit‐lamp
biomicroscopic examination, color  fundus photography, optical coherence  tomography  (OCT) and,  if needed,
fluorescein angiography. Overall, 224 anti‐VEGF naïve  subjects  including 56 patients  in early AMD group, 56
patients in intermediate AMD group, 56 patients in neovascular AMD group and 56 patients in no AMD group
were  recruited. For each group 28 male patients and 28  female patients were enrolled.  IGF‐1 hematic  levels
were  significantly  higher  (p<0.005)  in  the  neovascular  AMD  group  and  in  the  intermediate  AMD  group  in
comparison  to  no AMD  group; no  significant difference  between  early AMD  group  and no AMD  group was
found. Our analysis has shown an increment of IGF‐1 levels in both neovascular and intermediate stage of AMD
supporting the hypothesis that IGF‐1 may play a role in the pathogenesis of AMD.  
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VEGF drugs are the only approved therapeutic 
approach for the treatment of the disease [8–11]. 
Nevertheless, in addition to VEGF several humoral 
mediators including fibroblast growth factor, platelet-
derived growth factor, interleukin-6 (IL-6), interleukin-
8 (IL-8), monocyte chemoattractant protein-1, and 
insulin-like growth factor-1 (IGF-1) are altered in 
patients affected by neovascular AMD [12–15].  
 
IGF-1, also called somatomedin C, is a protein that is 
mainly secreted by the liver as a result of stimulation by 
growth hormone. IGF-1 is important for both the regu-
lation of normal physiology, as well as a number of 
pathological states, including cancer [16]. High IGF-1 
levels were associated with increased all cause mor-
tality, human studies support the notion that attenuation 
of GH/IGF-1 signaling may protect from age-related 
diseases and functional decline [17].  
 
In eyes affected by neovascular AMD, IGF-1 is 
increased in ocular fluid.  Furthermore IGF-1 receptors 
are expressed in retinal pigmented epithelium cells 
which are involved in neovascular AMD [18].  
 
To date, only one study investigated systemic IGF-1 
concentration in neovascular AMD patients, showing an 
increment in circulating IGF-1 levels in comparison to 
healthy controls. The authors demonstrated that early 
endothelial cells are increased in neovascular AMD and 


























However, in this study only patients with neovascular 
AMD were included, whereas patients with less 
advanced stages of AMD were not evaluated. There-
fore, it remains unclear if IGF-1 elevation is a con-
sequence of neovascular development in AMD patients, 
or if IGF-1 is primary involved in the pathogenesis of 
AMD, as in others aging related diseases, being a causal 
factor instead of the effect of AMD. 
 
The present study was therefore designed to evaluate 
the circulating IGF-1 levels in early, intermediate, and 





Overall 224 subjects met the study inclusion criteria and 
were included in the study, 56 patients in neovascular 
AMD group (32 type 1 cnv, 18 type 2 cnv, 6 type 3 cnv) 
(mean age 74±8 years), 56 patients in intermediate 
AMD group (mean age 73±8 years), 56 patients in early 
AMD group (mean age 74±1 years), and 56 patients in 
no AMD group (mean age 73±4 years). Mean best 
corrected visual acuity (BCVA) and intraocular pressure 
in four groups are reported in Table 1. For each group 
28 male patients and 28 female patients were enrolled.  
 
Mean IGF-1 values in all patients  
 
As shown in Table 2 the overall mean ± standard 





































BCVA logMAR 0.58±0.06 * 0.09±0.05 * 0.04±0.05 ° 0.01±0.02 <0.001 











Overall 146±40 * 127±29 ° 107±32 103±36 <0.001 
Males 169±34 * 143±30 ¨ 118±35 114±38 <0.001 
Females 123±32 * 111±16 § 97±25 92±30 <0.001 
Tukey HSD vs no AMD: * p<0.001, ° p=0.002,  ¨ p=0.011,  § p=0.038 
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between groups (P<0.001, ANOVA). Compared with 
the no AMD group, the mean IGF-1 values was 
significantly higher in the neovascular AMD group 
(Tukey HSD p<0.001) and in the intermediate AMD 
group (Tukey HSD p=0.002); no significant difference 
between early AMD group and no AMD group (Tukey 
HSD p =0.911), Figure 1. 
 
Mean IGF-1 values in male patients  
 
The overall mean ± (SD) IGF-1 values in male patients 
was significantly different between groups (P<0.001, 
ANOVA). Compared with the no AMD group, the 
mean ± (SD) IGF-1 values was significantly higher in 
the neovascular AMD group (Tukey HSD  p<0.001) 
and in the intermediate AMD group (Tukey HSD 
p=0.011); no difference was seen with early AMD 
group (Tukey HSD  p =0.975). 
 
Mean IGF-1 values in female patients 
 
The overall mean ± (SD) IGF-1 values was significantly 
different between groups (P<0.001, ANOVA). 
Compared with the no AMD group, the mean ± (SD) 
IGF-1 values was significantly higher in the neovas-































termediate AMD group (Tukey HSD p=0.038), but not 
in early AMD group (Tukey HSD  p =0.905). 
 
Correlation between IGF-1 and age 
 
A significant correlation was found between mean IGF-
1 values and age in early AMD group (r=-0. 342, 
p=0.010) and no AMD group (r=-0.317, p= 0.017), but 
no significant in neovascular AMD group (r=-0.117, 





AMD is a retinal degenerative disorder characterized by 
complex and not entirely understood pathogenesis. 
Several cytokines that promote retinal inflammation and 
angiogenesis has been suggested to be involved. Among 
these, there are clinical and experimental evidences on 
the role of retinal IGF-1 as a mediator of retinal inflam-
mation and neovascular formation [20,21]. To address 
this hypothesis, we evaluated circulating IGF-1 levels in 
patients with various stages of AMD. Our results 
indicate that serum levels of IGF-1 are higher in inter-
mediate and neovascular AMD patients in comparison 
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Dong Min Cha and associates [18] demonstrated the 
presence of higher levels of various cytokines, chemo-
kines and growth factors, including IGF-1, in the aque-
ous humor samples of patients affected by AMD in 
comparison with control subjects. 
 
In a previous study Machalinska and associates 
demonstrated higher IGF-1 plasma concentration of 
IGF-1 in patients with neovascular AMD in comparison 
to healthy subjects. Furthermore in their study the 
authors also reported an association of higher IGF-1 
levels with an increase of early endothelial progenitor 
cells. Albeit the latter association does not prove a cause 
to effect relationship, the authors hypothesized that 
angiogenesis under hypoxic conditions may represent 
the trigger that may explain the above mentioned 
observations [19]. They also suggested as a possible 
explanation a disturbed local synthesis of the cytokines 
and growth factors under conditions of chronic vascular 
endothelial injury. It should be kept in mind that IGF-1 
is a well-known retinal pro-angiogenic cytokine, and it 
has been demonstrated that IGF-1 induces retinal neo-
vascularization in animal models [22]. This may be of 
particular relevance under condition of long-term 
chronic hypoxia, in contrast to VEGF which may be 
more readily increased in the early phases of retinal 
ischemia. 
 
In agreement with the study of Machalinska, our results 
showed an increase in IGF-1 values in patients with 
neovascular AMD compared to healthy patients. How-
ever, a novel contribution of our present study is the 
observation of a significant increase in IGF-1 levels also 
in patients with intermediate stages of the disease. 
These data suggest that IGF-1 may be already elevated 
in stages of the retinal degeneration prior to the neo-
vascular formation. The association between IGF-1 and 
microvascular impairment in AMD may be not limited 
to the neovascular stage but may be already evident in a 
less severe stage (intermediate) of the disease. This 
hypothesis is also corroborated by the observed grading 
in IGF-1 levels that were higher in the more advanced 
stages of the disease. IGF-1 levels in AMD may be 
considered a predisposing factor to the disease or, 
alternatively it may be a consequence of the degene-
rative processes which characterize AMD.  Thus, these 
data are consistent with previous available data and may 
provide evidences for a pathogenetic or at least 
facilitating role of IGF-1 in AMD. 
 
Furthermore, an indirect confirmation of the role of 
changes in circulating IGF-1 values in patients with 
intermediate and neovascular AMD is that, in these 
groups of patients, our results did not show a significant 
correlation with age, which instead was found in healthy 
patients and in the group with early stage of disease. 
In a recent study Westwood and associates reported that 
IGF-1 plasma alterations are present in various neuro-
degenerative disorders. They demonstrated that lower 
serum levels of IGF-1 are associated with an increased 
risk of developing Alzheimer Disease (AD) dementia 
[23]. AMD is also characterized by retinal neuro-
degenerative processes [24] and previous studies have 
shown common pathogenetic features with AD [25]. 
Accordingly, is possible to suppose that IGF-1 is altered 
in various aging-related and neurodegenerative disor-
ders [26]. As a result, the role of IGF-1 in neuronal 
inflammation needs to be elucidated. 
 
It should be kept in mind that serum concentrations of 
IGF-1 are influenced by several factors, such as nutri-
tional factors, energy and protein intake, and BMI. 
These factors may play as confounders in data analysis 
and interpretation. Our data also confirmed gender-
differences in IGF-1 levels that were previously 
observed. [27] 
 
Our study has several limitations including the cross-
sectional nature of the study design with no longitudinal 
follow-up. In addition we didn’t evaluate IGF-1 levels 
in AMD patient affected by geographic atrophy, not 
clarifying whether the higher levels of IGF-1 in 
neovascular stage are linked to neovascular develop-
ment or to the progression of neurodegenerative pro-
cesses.  
 
In conclusion circulating IGF-1 levels are significantly 
higher in patients affected by intermediate and 
neovascular AMD in comparison with control subjects. 
Although future studies with larger sample are needed, 
our results suggest IGF-1 as a possible contributing 




In this observational, prospective, controlled study we 
recruited consecutive patients of more than 60 years 
with a diagnosis of early AMD, intermediate AMD, 
neovascular AMD, and healthy controls examined at the 
Department of Ophthalmology, University of Catania, 
Catania, Italy, between January 2017 and May 2018. In 
each group, according to the power of the study, 28 
male and 28 female patients were enrolled. The study 
was approved by the Institutional review board of the 
University of Catania. Written informed consent was 
obtained from all subjects enrolled in the study.  
 
Exclusion criteria were diabetes and any systemic 
condition which could bias IGF-1 measurements, 
including any clinical condition which may have caused 
an elevation of systemic inflammatory markers, regar-
dless of the cause that may have generated the rise. 
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Patients in overweight or obese were excluded from the 
study (BMI above 29). Similarly patients with low body 
weight (BMI below 17.5) or patient with clinically 
evident sarcopenia were excluded. In addition, patients 
who had undergone to any previous intravitreal therapy, 
previous cataract surgery in the last six months or 
patients who had clinical evidence of other retinal and 
ocular disease were also excluded. 
 
All patients enrolled were classified according to 4 
stages classification of AMD from Age-related eye 
disease study (AREDS)[28]: 
 
- No AMD (AREDS category 1) none or a few small 
drusen (<63 microns in diameter). 
- Early AMD (AREDS category 2) any or all of the 
following: multiple small drusen, few intermediate 
drusen (63 to 124 microns in diameter), or retinal 
pigment epithelial abnormalities. 
- Intermediate AMD (AREDS category 3) any or all of 
the following: extensive intermediate drusen, and at 
least one large drusen (≥ 125 microns in diameter), or 
geographic atrophy not involving the center of the 
fovea. 
- Neovascular AMD (AREDS category 4); any of the 
features of neovascular AMD. 
 
All patients underwent an ophthalmic examination 
including: best corrected visual acuity (BCVA), appla-
nation tonometry, slit-lamp biomicroscopic examina-
tion, Color fundus photography, optical coherence 
tomography (OCT) and, if needed, fluorescein angio-
graphy (FA) and indocyanine green angiography 
(ICGA). 
 
Color fundus photography of the central retina was 
performed by Visucam (Carl Zeiss Meditec, Inc, 
Dublin, California, USA). At least two color fundus 
images of each eye were acquired capturing the central 
field of the retina within a 45° view. Images were 
defined as gradable, if they fulfilled the following 
quality criteria allowing for the assessment of AMD: 
sufficient brightness and color contrast as well as full 
macular region captured. Images were excluded from 
AMD grading, if they revealed obscuring lesions or 
lesions considered to be the result of a competing retinal 
disease hampering AMD grading. Gradable images 
were examined by an experienced and trained ophthal-
mology consultant (M.R.); questionable findings were 
discussed with a second trained grader (T.A.).  
 
Spectral-domain OCT was carried out using the 
Spectralis HRA by Heidelberg (SD-OCT; Heidelberg 
Engineering, Heidelberg, Germany), FA and ICGA 
(Heidelberg retinal angiograph, Heidelberg Engine-
ering, Heidelberg, Germany) were performed in order to 
confirm the diagnoses in the neovascular AMD group. 
 
Serum IGF-1 was measured by standard immunoassay 
in all patients.  A 3 mL blood sample was drawn. This 
was obtained in the early morning at 08.00 after a 10 h 
overnight fasting. Prior to blood sampling patients were 
maintained in the supine position for 15 minutes.  
Samples were centrifuged, serum was aliquoted 
immediately and stored at -80°C in the central labora-
tory of our institution. 
 
The primary outcome measure of our study was the 
evaluation of IGF-1 circulating levels in case and 
control groups in male and female patients. Secondary 
outcome was to evaluate the correlation between 




The sample size (at least 26 males and 26 females in 
each group) was determined from the results of our 
preliminary data to detect, with an alpha of 0.05 and a 
90% power (two-tailed), a difference of 25 ng/ml in 
IGF-1 serum level between females with neovascular 
AMD and females with no AMD 
 
The values of parameters in four groups were compared 
by ANOVA; if significant, comparison with baseline 
value was performed by Tukey HSD (honestly 
significant difference) test. In each group, correlation 
between IGF-1 levels and age was analyzed by 
Pearson's Correlation Coefficient. SPSS 21.0 (V.21, 
Armonk, NY, USA) was used for statistical analysis. P 
values < 0.05 was considered as statistically significant. 
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